Alnylam Pharmaceuticals, Inc. Share Price Today: Live Updates & Key Insights
Alnylam Pharmaceuticals, Inc. share price today is $270.91, up 1.13%. The stock opened at $268.89 against the previous close of $268.74, with an intraday high of $275.5 and low of $265.65.
Alnylam Pharmaceuticals, Inc. Share Price Chart
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Share Price Performance
Alnylam Pharmaceuticals, Inc. Institutional Holdings
Alnylam Pharmaceuticals, Inc. Market Status
Alnylam Pharmaceuticals, Inc. Fundamentals
Market Cap 35880.17 M
PB Ratio 33.1478
PE Ratio 67.185
Enterprise Value 33910.36 M
Total Assets 4966.33 M
Volume 1151029
Alnylam Pharmaceuticals, Inc. Company Financials
About Alnylam Pharmaceuticals, Inc. & investment objective
Company Information Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Organisation Biotechnology
Employees 2500
Industry Biotechnology
CEO Dr. Yvonne L. Greenstreet M.B.A., M.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
Alnylam Pharmaceuticals, Inc. FAQs
What is the share price of Alnylam Pharmaceuticals, Inc. today?
The current share price of Alnylam Pharmaceuticals, Inc. is $270.91.
Can I buy Alnylam Pharmaceuticals, Inc. shares in India?
Yes, Indian investors can buy Alnylam Pharmaceuticals, Inc. shares by opening an international trading and demat account with Motilal Oswal.
How to buy Alnylam Pharmaceuticals, Inc. shares in India?
You can easily invest in Alnylam Pharmaceuticals, Inc. shares from India by:
- Direct Investment:
Opening an international trading account with Motilal Oswal which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy Alnylam Pharmaceuticals, Inc. shares. - Indirect Investment:
Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of Alnylam Pharmaceuticals, Inc..
Can I buy fractional shares of Alnylam Pharmaceuticals, Inc.?
Yes, many platforms allow you to buy fractional shares starting from as low as $1.
What is the market capitalization value of Alnylam Pharmaceuticals, Inc.?
Alnylam Pharmaceuticals, Inc. has a market cap of $35880.17 M.
In which sector does Alnylam Pharmaceuticals, Inc. belong?
Alnylam Pharmaceuticals, Inc. operates in the Biotechnology sector.
What documents are required to invest in Alnylam Pharmaceuticals, Inc. stocks?
To invest, you typically need:
What is the PE and PB ratio of Alnylam Pharmaceuticals, Inc.?
The PE ratio of Alnylam Pharmaceuticals, Inc. is 67.19 and the PB ratio is 33.15.